Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
Go back to Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 126.75 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $126.75 | 52 Week High | $118.49 | |||
| Open | $126.75 | 52 Week Low | $55.00 | |||
| Day High | $126.75 | P/E | N/A | |||
| Day Low | $126.75 | EPS | $-0.56 | |||
| Volume | 720 | |||||
